Last reviewed · How we verify
Candesartan cilexetil and hydrochlorothiazide
Candesartan cilexetil and hydrochlorothiazide, marketed by Takeda, is a combination therapy primarily indicated for hypertension. The drug's key strength lies in its dual mechanism of action, which can effectively manage blood pressure through both angiotensin II receptor blockade and diuretic effects. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Candesartan cilexetil and hydrochlorothiazide |
|---|---|
| Also known as | Blopress, Atacand®, Amias, Ratacand, Kenzen |
| Sponsor | Takeda |
| Drug class | Thiazide Diuretic [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Hypertension
Boxed warnings
- WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue candesartan cilexetil and hydrochlorothiazide tablets as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity
Common side effects
- Upper respiratory tract infection
- Back pain
- Dizziness
- Influenza-like symptoms
Serious adverse events
- Angioedema
- Rhabdomyolysis
- Hepatitis
- Agranulocytosis
- Neutropenia
- Leukopenia
- Anaphylactic reactions
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Aplastic anemia
Drug interactions
- Non-Steroidal Anti-Inflammatory Agents (NSAIDs) including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
- Lithium
- Angiotensin Receptor Blockers (ARBs), ACE Inhibitors, or Aliskiren
- Potassium-sparing Diuretics, Potassium Supplements, Potassium-Containing Salt Substitutes, or Other Drugs That Raise Serum Potassium Levels
- Aliskiren
- Alcohol, Barbiturates, or Narcotics
- Antidiabetic Drugs (Oral Agents and Insulin)
- Diazoxide
- Ion Exchange Resins (Cholestyramine or Colestipol)
Key clinical trials
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- The Precision Hypertension Care Study (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323 (PHASE1)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control (PHASE3)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (PHASE3)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candesartan cilexetil and hydrochlorothiazide CI brief — competitive landscape report
- Candesartan cilexetil and hydrochlorothiazide updates RSS · CI watch RSS
- Takeda portfolio CI